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morphology. BPA-treated animals (either 
50  or  500  μg/day)  had  smaller  ovaries 
(although body weight was unaffected) and 
lower numbers of antral follicles. Animals 
treated with 500 μg/day BPA as neonates 
also  had  ovarian  cysts,  a  phenomenon 
shared with other animal models of PCOS 
(Sotomayor-Zarate et al., 2008).
Since ovarian morphology and circulat-
ing sex hormone levels are altered, is fertil-
ity also impaired by neonatal exposure to 
BPA? To address this question, oocytes were 
counted in the ampulla of the oviduct on 
the morning of estrus. Strikingly, animals 
that had been treated with 500 μg/day BPA 
as neonates did not ovulate; however, those 
treated with 50 or 5 μg/day BPA presented 
the same number of oocytes as controls. 
How did these treatments affect overall fer-
tility? Unsurprisingly, animals that had been 
exposed to 500 μg/day BPA did not deliver 
any pups. However, those animals treated 
with 50 μg/day BPA delivered ∼30% fewer 
pups, indicating an effect on fertility inde-
pendent of reduced numbers of oocytes. 
These results suggest that juvenile expo-
sure to BPA can have lasting effects on the 
mammalian reproductive cycle throughout 
adulthood.
This  work  introduces  a  new  way  to 
induce  PCOS-like  traits  in  a  rodent 
model. Yet, metabolic malfunctions also 
occur  in  clinical  PCOS;  these  were  not 
investigated. In fact, while human PCOS 
is associated with increased risk for obes-
ity, these BPA-treated animals showed no 
difference in weight. Thus, this new model 
of PCOS may be best suited for studying 
the mechanisms of onset of the androgen 
feedback  cascade  that  is  hypothesized 
to initiate PCOS. Rising androgen levels 
during puberty were postulated to reduce 
negative progesterone feedback on GnRH 
pulsatility and initiate the adult pattern of 
GnRH release (Blank et al., 2007). An early 
rise  in  androgen  levels  could  therefore 
drogenism (e.g., hirsutism), and polycystic 
ovaries as well as metabolic symptoms, e.g., 
insulin  resistance  and  obesity  (Barontini 
et al., 2001). However, the primary defects 
in the hypothalamus–pituitary-ovary axis 
underlying  this  disorder  have  not  been 
clearly  identified.  Women  with  PCOS 
show an acceleration of the GnRH pulse 
generator activity. This causes inappropri-
ate   gonadotropin synthesis and release with 
elevated LH and low FSH levels, resulting in 
excess production of androgens (Barontini 
et al., 2001). The heterogeneity of this dis-
order together with the absence of good 
animal  models  has  caused  tremendous 
problems  studying  this  syndrome  in  the 
laboratory. A recent study (Fernandez et al., 
2010) introduces a new animal model of 
PCOS  that  addresses  shortcomings  of 
existing models and may help dissect the 
molecular causes of this syndrome.
Abnormally high androgen levels may 
contribute to PCOS, potentially reducing 
natural negative feedback on GnRH release 
and LH levels. Fernandez et al. (2010) there-
fore quantified the change in sex hormone 
levels  in  adulthood  caused  by  neonatal 
exposure  to  BPA.  Rats  given  subcutane-
ous injections daily of 50 or 500 μg/day 
from postnatal days 1–10 had higher lev-
els of circulating testosterone and estrogen 
and lower levels of progesterone as adults. 
Androgen and serum BPA levels are both 
elevated in women with PCOS (Eagleson 
et  al.,  2000).  However,  previous  studies 
were unable to discern whether BPA raised 
testosterone  levels  or  whether  elevated 
testosterone levels prevented clearance of 
BPA. These new results suggest that juve-
nile exposure to BPA can cause increased 
androgen levels in adulthood.
GnRH release frequency increases upon 
neonatal administration of BPA (Fernandez 
et al., 2009). This could be the result of 
impaired ovarian functionality. Therefore, 
Fernandez et al. (2010) examined ovarian 
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For over 30 years, scientists have focused 
on  the  impact  of  endocrine  disrupting 
chemicals (EDC) on human health. These 
synthetic or natural compounds can mimic 
and/or  antagonize  the  action  of  endog-
enous hormones. Exposure to EDCs has 
been  linked  to  reduced  fertility,  onset 
of  diseases  like  diabetes,  endometriosis, 
and some cancers (Diamanti-Kandarakis 
et al., 2009). However, exactly how EDCs 
cause these effects is not clear. Many of 
the observed effects can appear through-
out life, even though exposure might have 
occurred only shortly during early devel-
opment. Exposure dose has a tremendous 
effect, with very low doses causing adverse 
effects even though being well below the 
determined “no effect” levels (Diamanti-
Kandarakis et al., 2009).
One  of  the  investigated  EDCs  is 
Bisphenol-A (BPA), a chemical produced 
in large quantities for production of poly-
carbonate plastics and epoxy resin. BPA has 
adverse  effects  on  fertility,  development, 
and behavior in lab animals (Richter et al., 
2007). Furthermore, a recent study showed 
that BPA levels were significantly higher in 
women with polycystic ovarian syndrome 
(PCOS) compared to normal women and 
could possibly be one of many underly-
ing  causes  of  this  disorder  (Kandaraki 
et al., 2011).
Polycystic ovarian syndrome is a com-
mon  endocrine  disorder  in  women  of 
reproductive age, characterized by ovula-
tory and menstrual dysfunction, hyperan-
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  initiate this process early, tipping hormone 
production in favor of a positive feedback 
cascade of progressive GnRH release and 
androgen  production  (Tsutsumi  and 
Webster, 2009). Current animal models 
bypass the onset of androgen imbalances 
by their direct introduction. With a bet-
ter understanding of the onset of PCOS, 
it may be possible to develop early treat-
ments that interrupt the development of 
this syndrome.
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